Global DNA Methylation Index for Early Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and diagnosing hepatic and gastric cancers, such as HCC and GC, lack effective molecular biomarkers, leading to late-stage diagnoses and inadequate treatment options, particularly for patients with advanced disease.
Innovation Solution
A method involving the calculation of a Global DNA Methylation Index (GDMI) by determining the ratio of 5-methyl-2′-deoxycytidine to 2′-deoxycytidine in biological samples, combined with specific promoter methylation analysis of genes like RASSF1A, SSBP2, and B4GALT1, to differentiate between cancerous and non-cancerous tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiological diagnosis techniques (CT, MRI, contrast imaging) are used for HCC detection, then diagnostic capability is improved, but diagnostic accuracy deteriorates in early-stage tumors due to dependence on arterial hypervascularization
Solution Approach 1:
The patent introduces DNA methylation analysis as an intermediary biomarker to bridge the gap between radiological imaging and early HCC detection. By measuring global DNA hypomethylation and promoter-specific hypermethylation patterns, the method provides a molecular mediator that can detect early-stage HCC before radiological features become apparent, thus resolving the contradiction between having diagnostic capability and achieving diagnostic accuracy in early tumors
Solution Approach 2:
The patent replaces the mechanical/radiological detection system (which relies on physical imaging of hypervascularization) with a molecular detection system based on DNA methylation analysis. This substitution allows detection of HCC at the molecular level before anatomical or vascular changes are detectable by imaging, thereby maintaining diagnostic capability while improving measurement precision for early-stage tumors
2Reliability
If endoscopy is used for GC detection, then screening coverage is improved, but diagnostic accuracy deteriorates due to false-negative rates and difficulty distinguishing early GC from benign conditions
Solution Approach 1:
The patent introduces DNA methylation analysis as a molecular intermediary to complement endoscopic screening. By analyzing global DNA hypomethylation and promoter-specific hypermethylation patterns in gastric tissue, the method provides an additional diagnostic layer that helps distinguish early GC from benign peptic ulcer or gastritis, thereby maintaining screening coverage while improving diagnostic accuracy and reducing false-negative rates
Solution Approach 2:
The patent creates a composite diagnostic approach by combining endoscopic visual inspection with molecular DNA methylation analysis. This composite methodology integrates two different detection modalities (visual and molecular) to overcome the limitations of each individual method, thereby maintaining the broad screening coverage of endoscopy while improving diagnostic accuracy through the additional molecular information
3Adaptability or versatility
If current treatment modalities are applied to HCC patients, then treatment options are provided, but treatment effectiveness deteriorates because most patients present with advanced disease
Solution Approach 1:
The patent enables preliminary detection and risk stratification of HCC through DNA methylation analysis before tumors reach advanced stages. By identifying patients with early-stage HCC or those at high risk through molecular biomarkers, the system allows for preliminary intervention with curative treatments (resection, transplantation, ablation) before the disease progresses, thereby maintaining treatment option versatility while dramatically improving treatment effectiveness
Data Source
AI summary
The present invention provides methods of determination of a global DNA methylation index (GDMI) in a sample from a subject, using a variety of methods which can detect global, genome-wide, and gene-specific DNA methylation to create methylation portraits that can be used for early detection, diagnosis, and clinical management in the personalized medicine space. Further, the invention provides methods of diagnosis of cancer, including gastric cancer and hepatocellular cancer in a subject, by comparing the GDMI in a sample obtained from a subject to the methylation index of standard controls. These methods allow diagnosis of gastric carcinoma and liver cancer in patients who may be asymptomatic or have inconclusive pathology, and allowing earlier treatment of the subject.